This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB04882/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04882/identifier/chemspider/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04882/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04882/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04882/identifier/kegg-drug/

Statements

Subject Item
n2:DB04882
rdf:type
n3:Drug
n3:description
Edotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.
n3:generalReferences
# Saif MW, Diasio RB: Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15929804 # Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y: Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemother Pharmacol. 2006 Aug;58(2):173-82. Epub 2005 Nov 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16308697 # Vrdoljak E, Boban M, Saratlija-Novakovic Z, Jovic J: Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report. Croat Med J. 2006 Apr;47(2):305-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16625697 # Ciomei M, Croci V, Ciavolella A, Ballinari D, Pesenti E: Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin Cancer Res. 2006 May 1;12(9):2856-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16675581 # Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T: A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2007 Jan;59(1):139-47. Epub 2006 Jul 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16819636 # Ciomei M, Croci V, Stellari F, Amboldi N, Giavarini R, Pesenti E: Antitumor activity of edotecarin in breast carcinoma models. Cancer Chemother Pharmacol. 2007 Jul;60(2):229-35. Epub 2006 Nov 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17089166
n3:group
investigational
n3:halfLife
20 to 25 hours
n3:indication
Clinical studies with edotecarin have shown activity in subjects with colorectal cancer, esophageal cancer and other solid tumors.
owl:sameAs
n13:DB04882
dcterms:title
Edotecarin
adms:identifier
n6:133161 n8:151078 n9:10486862 n10:DB04882 n11:D03954
n3:mechanismOfAction
Edotecarin inhibits the enzyme topoisomerase I through stabilization of the DNA-enzyme complex and enhanced single-strand DNA cleavage, resulting in inhibition of DNA replication and decreased tumor cell proliferation.
n3:synonym
ED-749 Edotecarina Edotecarinum
n3:IUPAC-Name
n4:271B5CA9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5CAF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5CAE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5CAB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5CAC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5CAD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5CA7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5CA8-363D-11E5-9242-09173F13E4C5 n4:271B5CA5-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5CA6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5CB5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5CB6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5CB0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5CB1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5CB3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5CB2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5CB4-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
174402-32-5
n3:category
n3:Bioavailability
n4:271B5CBB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5CBD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5CBE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5CBA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5CB9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5CBC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5CAA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5CB7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5CB8-363D-11E5-9242-09173F13E4C5